• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于炎症性肠病的饮食和微生物群导向疗法2.0

Diet and Microbiome-Directed Therapy 2.0 for IBD.

作者信息

Ananthakrishnan Ashwin N, Whelan Kevin, Allegretti Jessica R, Sokol Harry

机构信息

Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

Department of Nutritional Sciences, King's College London, London, United Kingdom.

出版信息

Clin Gastroenterol Hepatol. 2025 Feb;23(3):406-418. doi: 10.1016/j.cgh.2024.05.049. Epub 2024 Jul 9.

DOI:10.1016/j.cgh.2024.05.049
PMID:38992408
Abstract

Inflammatory bowel disease (IBD) comprises chronic and relapsing disorders of the gastrointestinal tract, characterized by dysregulated immune responses to the gut microbiome. The gut microbiome and diet are key environmental factors that influence the onset and progression of IBD and can be leveraged for treatment. In this review, we summarize the current evidence on the role of the gut microbiome and diet in IBD pathogenesis, and the potential of microbiome-directed therapies and dietary interventions to improve IBD outcomes. We discuss available data and the advantages and drawbacks of the different approaches to manipulate the gut microbiome, such as fecal microbiota transplantation, next-generation and conventional probiotics, and postbiotics. We also review the use of diet as a therapeutic tool in IBD, including the effects in induction and maintenance, special diets, and exclusive enteral nutrition. Finally, we highlight the challenges and opportunities for the translation of diet and microbiome interventions into clinical practice, such as the need for personalization, manufacturing and regulatory hurdles, and the specificity to take into account for clinical trial design.

摘要

炎症性肠病(IBD)包括胃肠道的慢性复发性疾病,其特征是对肠道微生物群的免疫反应失调。肠道微生物群和饮食是影响IBD发病和进展的关键环境因素,可用于治疗。在本综述中,我们总结了关于肠道微生物群和饮食在IBD发病机制中的作用,以及微生物群导向疗法和饮食干预改善IBD结局的潜力的现有证据。我们讨论了现有数据以及不同方法操纵肠道微生物群的优缺点,如粪便微生物群移植、新一代和传统益生菌以及后生元。我们还综述了饮食作为IBD治疗工具的应用,包括诱导和维持效果、特殊饮食和全肠内营养。最后,我们强调了将饮食和微生物群干预转化为临床实践的挑战和机遇,如个性化需求、制造和监管障碍以及临床试验设计中需考虑的特异性。

相似文献

1
Diet and Microbiome-Directed Therapy 2.0 for IBD.用于炎症性肠病的饮食和微生物群导向疗法2.0
Clin Gastroenterol Hepatol. 2025 Feb;23(3):406-418. doi: 10.1016/j.cgh.2024.05.049. Epub 2024 Jul 9.
2
Therapeutic modulation of gut microbiota in inflammatory bowel disease: More questions to be answered.炎症性肠病中肠道微生物群的治疗性调节:更多问题有待解答。
J Dig Dis. 2016 Dec;17(12):800-810. doi: 10.1111/1751-2980.12422.
3
Gut microbiota in the pathogenesis of inflammatory bowel disease.肠道微生物群在炎症性肠病发病机制中的作用
Clin J Gastroenterol. 2018 Feb;11(1):1-10. doi: 10.1007/s12328-017-0813-5. Epub 2017 Dec 29.
4
The emerging role of the gut microbiota and its application in inflammatory bowel disease.肠道微生物群的新兴作用及其在炎症性肠病中的应用。
Biomed Pharmacother. 2024 Oct;179:117302. doi: 10.1016/j.biopha.2024.117302. Epub 2024 Aug 19.
5
Microbiota in Inflammatory Bowel Disease Pathogenesis and Therapy: Is It All About Diet?微生物群在炎症性肠病发病机制和治疗中的作用:一切都与饮食有关吗?
Nutr Clin Pract. 2015 Dec;30(6):760-79. doi: 10.1177/0884533615606898. Epub 2015 Oct 9.
6
Nutritional Support and Probiotics as a Potential Treatment of IBD.营养支持和益生菌作为治疗 IBD 的一种潜在方法。
Curr Drug Targets. 2020;21(14):1417-1427. doi: 10.2174/1389450121666200504075519.
7
Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood.炎症性肠病患儿至成人的肠道微生物组调节治疗进展。
Int J Mol Sci. 2021 Nov 19;22(22):12506. doi: 10.3390/ijms222212506.
8
Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools.炎症性肠病中的肠道微生物群调节:从旧范式到革命性工具
Int J Mol Sci. 2025 Mar 27;26(7):3059. doi: 10.3390/ijms26073059.
9
The Gut Microbiome Advances Precision Medicine and Diagnostics for Inflammatory Bowel Diseases.肠道微生物组推动炎症性肠病的精准医学和诊断进展。
Int J Mol Sci. 2024 Oct 19;25(20):11259. doi: 10.3390/ijms252011259.
10
Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients.调节炎症性肠病患者肠道微生物群的组成和代谢活性
Int J Mol Sci. 2016 Apr 19;17(4):578. doi: 10.3390/ijms17040578.

引用本文的文献

1
Dietary Interventions and Oral Nutritional Supplementation in Inflammatory Bowel Disease: Current Evidence and Future Directions.炎症性肠病的饮食干预与口服营养补充:当前证据与未来方向
Nutrients. 2025 May 30;17(11):1879. doi: 10.3390/nu17111879.
2
Innate Lymphoid Cells in Inflammatory Bowel Disease.炎症性肠病中的固有淋巴细胞
Cells. 2025 Jun 2;14(11):825. doi: 10.3390/cells14110825.
3
Crosstalk Between Bile Acids and Intestinal Epithelium: Multidimensional Roles of Farnesoid X Receptor and Takeda G Protein Receptor 5.
胆汁酸与肠上皮细胞之间的相互作用:法尼酯X受体和武田G蛋白偶联受体5的多维作用
Int J Mol Sci. 2025 Apr 29;26(9):4240. doi: 10.3390/ijms26094240.
4
Developing IBD counsellors in low- and middle-income countries: bridging gaps in patient care.在低收入和中等收入国家培养炎症性肠病顾问:弥合患者护理差距
EClinicalMedicine. 2025 Apr 24;83:103218. doi: 10.1016/j.eclinm.2025.103218. eCollection 2025 May.
5
The role of colonic microbiota amino acid metabolism in gut health regulation.结肠微生物群氨基酸代谢在肠道健康调节中的作用。
Cell Insight. 2025 Jan 10;4(2):100227. doi: 10.1016/j.cellin.2025.100227. eCollection 2025 Apr.
6
Multiomics analysis reveals the potential mechanism of high-fat diet in dextran sulfate sodium-induced colitis mice model.多组学分析揭示了高脂饮食在葡聚糖硫酸钠诱导的结肠炎小鼠模型中的潜在机制。
Food Sci Nutr. 2024 Aug 30;12(10):8309-8323. doi: 10.1002/fsn3.4426. eCollection 2024 Oct.